OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 331 participants.

Also called NCT01182493

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 331 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01182493
Other papers using this trial's data
  • Complex Assessment of Metabolic Effectiveness of Insulin Pump Therapy in Patients with Type 2 Diabetes Beyond HbA1c Reduction Diabetes technology & therapeutics, 2018-02 DOI, PubMed 29215299, PMC5771538 In the PMC Open Access subset under CC BY.
  • Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: An analysis from the OpT2mise randomized trial Diabetes, obesity & metabolism, 2017-10 DOI, PubMed 28374511
  • Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial Lancet (London, England), 2014-10-04 DOI, PubMed 24998009

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Canada, France, Germany, Hungary, Israel, Italy, Netherlands, North Macedonia, Serbia, South Africa, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01182493. Randomized; no masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2014-02 (actual). Results posted on 2016-03-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
Acronym
OpT2mise
Condition
Diabetes Mellitus, Type 2
Intervention (Device)
Insulin Pump (Medtronic Minimed Paradigm® VEO)
Lead sponsor
Medtronic MiniMed, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01182493
Content hash
1f911913b9896fe807b7e5549e6fc482c426b65460d5e14bb45b2256fb8cf971